Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 microg Nomegestrol Acetate (NOMAC) and 300 microg Estradiol (E2), or 900 microg Nomegestrol Acetate (NOMAC) and 300 microg Estradiol (E2), or 100 microg Etonogestrel (ENG) and 300 microg E2, or 125 microg Etonogestrel (ENG) and 300 microg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)

Next Previous
Trial Profile

A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 microg Nomegestrol Acetate (NOMAC) and 300 microg Estradiol (E2), or 900 microg Nomegestrol Acetate (NOMAC) and 300 microg Estradiol (E2), or 100 microg Etonogestrel (ENG) and 300 microg E2, or 125 microg Etonogestrel (ENG) and 300 microg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol/etonogestrel (Primary) ; Estradiol/nomegestrol (Primary) ; Ibuprofen
  • Indications Dysmenorrhoea
  • Focus Therapeutic Use
  • Sponsors Organon

    • Most Recent Events

    • 12 Nov 2018 Primary endpoint (Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2) has been met as per results published in the Contraception
    • 12 Nov 2018 Results published in the Contraception
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top